Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Clinicopathological Characteristics of Subcutaneous Panniculitis-like T-Cell Lymphoma in Asian Population: A Retrospective Cohort of 48 Patients

BEN Ponvilawan, Pornlada Likasitwatanakul, Panitta Sitthinamsuwan, Noppadol Siritanaratkul, Archrob Khuhapinant, Manasmon Chairatchaneeboon, Danai Samutpradit, Ployploen Phikulsod

Blood (2021) 138 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2021-149952

Published: 2021

Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok

Blood (2018) 131 (2): 263–265.

https://doi.org/10.1182/blood-2017-06-790121

Published: 2018

Includes: Supplemental data

Journal Articles

An Urgent Need for Improving Thalassemia Care in Adult Patients Due to a Wide Gap on Current Real-Life Practice and Recommended Clinical Practice Guidelines

Supachai Ekwattanakit, BSc, PhD MD, Chattree Hantaweepant, MD, Archrob Khuhapinant, MD PhD, Noppadol Siritanaratkul, MD, Vip Viprakasit, MD DPhil

Blood (2017) 130 (Supplement 1): 952.

https://doi.org/10.1182/blood.V130.Suppl_1.952.952

Published: 2017

Journal Articles

Longitudinal Serum Ferritin Cut-Off Level for Cardiac Iron Overload Prediction in Transfusion-Dependent Thalassemia in a Resource Limited Country

Supachai Ekwattanakit, PhD MD, Pairash Saiviroonporn, PhD, Kleebsabai Sanpakit, MD, Noppadol Siritanaratkul, MD, Jassada Buaboonnam, MD, Archrob Khuhapinant, PhD MD, Boonying Rerkudom, Stephan Erberich, PhD, John C Wood, MD PhD, Rungroj Krittayaphong, MD, Vip Viprakasit, MD DPhil

Blood (2016) 128 (22): 1282.

https://doi.org/10.1182/blood.V128.22.1282.1282

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Blood (2016) 127 (6): 713–721.

https://doi.org/10.1182/blood-2015-09-665018

Published: 2016

Includes: Supplemental data

Journal Articles

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Noppadol Siritanaratkul, Jong Wook Lee, Jun Ma, Mustafa Pehlivan, Elena Volodicheva, Qian Jiang, Fatiha Grifi, Bor-Sheng Ko, Raymond Wong, Vernon Louw, Abderrahim Khelif, Ali El-Ali, Jackie Han, Alfonso Losco, Osman Ilhan

Blood (2015) 126 (23): 2152.

https://doi.org/10.1182/blood.V126.23.2152.2152

Published: 2015

Journal Articles

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, Yong-Rong Lai

Blood (2015) 126 (23): 2153.

https://doi.org/10.1182/blood.V126.23.2153.2153

Published: 2015

Journal Articles

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Blood (2015) 126 (23): 4230.

https://doi.org/10.1182/blood.V126.23.4230.4230

Published: 2015

Journal Articles

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

M Domenica Cappellini, Vip Viprakasit, Yesim Aydinok, John B Porter, Yong-Rong Lai, Noppadol Siritanaratkul, Zeynep Karakas, Antonis Kattamis, Candace Wang, Zewen Zhu, Felicity Schaefer, Ali T Taher

Blood (2015) 126 (23): 3366.

https://doi.org/10.1182/blood.V126.23.3366.3366

Published: 2015

Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 3026.

https://doi.org/10.1182/blood.V126.23.3026.3026

Published: 2015

Journal Articles

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Blood (2014) 124 (21): 4742.

https://doi.org/10.1182/blood.V124.21.4742.4742

Published: 2014

Journal Articles

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Tadeusz Robak, MD, Huiqiang Huang, MD, Jie Jin, MD, Jun Zhu, MD, Ting Liu, Olga S Samoilova, MD, Halyna Pylypenko, MD, Gregor Verhoef, MD PhD, Noppadol Siritanaratkul, MD, Evgenii A Osmanov, MD PhD, Julia Alexeeva, MD PhD, Juliana Pereira, PhD, Jiri Mayer, Prof., MD PhD, Xiaonan Hong, MD, Yoshiharu Maeda, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 4412.

https://doi.org/10.1182/blood.V124.21.4412.4412

Published: 2014

Journal Articles

Incidence and Characteristics of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis in Thailand: A 5-Year Retrospective Study

Archrob Khuhapinant, MD PhD, Kamoltip Lertchaisataporn, MD, Ployploen Phikulsod, MD, Noppadol Siritanaratkul, MD

Blood (2014) 124 (21): 5563.

https://doi.org/10.1182/blood.V124.21.5563.5563

Published: 2014

Journal Articles

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2014) 124 (21): 2120.

https://doi.org/10.1182/blood.V124.21.2120.2120

Published: 2014

Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC

Blood (2012) 120 (21): 1629.

https://doi.org/10.1182/blood.V120.21.1629.1629

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Blood (2012) 120 (21): 5035.

https://doi.org/10.1182/blood.V120.21.5035.5035

Published: 2012

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

NARROW

Clinicopathological Characteristics of Subcutaneous Panniculitis-like T-Cell Lymphoma in Asian Population: A Retrospective Cohort of 48 Patients

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

An Urgent Need for Improving Thalassemia Care in Adult Patients Due to a Wide Gap on Current Real-Life Practice and Recommended Clinical Practice Guidelines

Longitudinal Serum Ferritin Cut-Off Level for Cardiac Iron Overload Prediction in Transfusion-Dependent Thalassemia in a Resource Limited Country

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Incidence and Characteristics of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis in Thailand: A 5-Year Retrospective Study

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only